"Measurable vs non-measurable "
"≥10 mm at spiral CT with 5 mm reconstructed section thickness in the axial plane (not the sagittal or coronal planes at CT or MR imaging). Exception are lymph nodes when used as target lesions, which must be ≥15 in short axis."
"up to a maximum of 5 measurable lesions, with no more than 2 of the same organ (e.g. if a patient has two organs involved, then a maximum of 4 target lesions can be chosen). The chosen lesions should be representative of all the involved organs."
"sum of diameters (SOD) of all target lesions should be reported on the initial and all follow-up studies. The initial SOD is recorded as the baseline sum diameters (BSD), which is compared to on subsequent studies to determine response criteria (see below)."
"complete response (CR):"
"partial response (PR):"
"progressive disease (PD):"
"stable disease (SD):"
"Immune-related Response Criteria (irRC): introduced in 2009"
"Immune-related Response Evaluation Criteria in Solid Tumours (irRECIST): introduced in 2013"
"Immune Response Evaluation Criteria in Solid Tumours (iRECIST): introduced in 2017"
"Immune-modified Response Evaluation Criteria in Solid Tumours (imRECIST): introduced in 2018"
"Immunotherapy Response Assessment in Neuro-Oncology (iRANO): for assessment of brain tumours treated with immunotherapy, introduced in 2015"
"Choi Response Criteria"
"ultrasound is not considered adequately reproducible or reliable"
"sum of diameters (SOD) of all target lesions should be reported on the initial and all follow-up studies. The initial SOD is recorded as the baseline sum diameters (BSD), which is compared to on subsequent studies to determine response criteria (see below)."
"sum of diameters (SOD) of all target lesions should be reported on the initial and all follow-up studies. The initial SOD is recorded as the baseline sum diameters (BSD), which is compared to on subsequent studies to determine response criteria (see below)."
"at least 30% decrease in SOD of target lesions compared to baseline sum diameters (BSD)"
"at least 20% relative and 5 mm absolute increase of SOD of target lesions compared to smallest SOD ever recorded for the patient"
"at least 20% relative and 5 mm absolute increase of SOD of target lesions compared to smallest SOD ever recorded for the patient"
"PERCIST 1.0"
Expected headings
"Measurement"
"Measurable vs non-measurable "
"Measurement methods"
"Target vs non-target"
"Response criteria"
"The RECIST criteria can be used with CT, MRI or conventional radiography (in some instances) 3,8."
"Re-evaluation of a prescribed number of thus defined lesions over subsequent scans classifies the patient's disease burden as improving, stable or progressive."
"multiple non-target lesions of the same organ can be recorded together (e.g. "multiple liver metastases")"